PLD3 in Alzheimer's disease
- PMID: 24935720
- DOI: 10.1007/s12035-014-8779-5
PLD3 in Alzheimer's disease
Abstract
Rare coding variants in the phospholipase D3 (PLD3) gene, also known as HU-K4, have recently been identified to increase the risk for late-onset Alzheimer's disease (LOAD) by the whole exome sequencing (WES) in 14 large LOAD families and follow-up analyses of the candidate variants in several large independent LOAD case-control data series. PLD3 is highly expressed in the brain, especially mainly in neurons, but at a lower level in almost all tissues. The level of PLD3 was found to be downregulated in Alzheimer's disease (AD) brains, which was negatively correlated with amyloid precursor protein (APP) and amyloid-β (Aβ) levels. These findings suggested that PLD3 might be involved in AD pathogenesis through APP processing. Here, we briefly summarize the biochemical properties of PLD3, review recent genetic and expression findings of PLD3 that related to AD, and also speculate on the possible roles of PLD3 in the progression of this disease. Based on the contributing effects of PLD3 in AD pathogenesis, targeting PLD3 may provide new opportunities for AD therapeutic strategies.
Similar articles
-
Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease.Nature. 2014 Jan 23;505(7484):550-554. doi: 10.1038/nature12825. Epub 2013 Dec 11. Nature. 2014. PMID: 24336208 Free PMC article.
-
PLD3 epigenetic changes in the hippocampus of Alzheimer's disease.Clin Epigenetics. 2018 Sep 12;10(1):116. doi: 10.1186/s13148-018-0547-3. Clin Epigenetics. 2018. PMID: 30208929 Free PMC article.
-
PLD3 is a neuronal lysosomal phospholipase D associated with β-amyloid plaques and cognitive function in Alzheimer's disease.PLoS Genet. 2021 Apr 8;17(4):e1009406. doi: 10.1371/journal.pgen.1009406. eCollection 2021 Apr. PLoS Genet. 2021. PMID: 33830999 Free PMC article.
-
Alzheimer's disease.Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Subcell Biochem. 2012. PMID: 23225010 Review.
-
Impact of late-onset Alzheimer's genetic risk factors on beta-amyloid endocytic production.Cell Mol Life Sci. 2018 Jul;75(14):2577-2589. doi: 10.1007/s00018-018-2825-9. Epub 2018 Apr 27. Cell Mol Life Sci. 2018. PMID: 29704008 Free PMC article. Review.
Cited by
-
The V-ATPase complex component RNAseK is required for lysosomal hydrolase delivery and autophagosome degradation.Nat Commun. 2024 Sep 5;15(1):7743. doi: 10.1038/s41467-024-52049-3. Nat Commun. 2024. PMID: 39231962 Free PMC article.
-
Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer's disease: findings based on urine proteomics and machine learning.Alzheimers Res Ther. 2023 Nov 4;15(1):191. doi: 10.1186/s13195-023-01324-4. Alzheimers Res Ther. 2023. PMID: 37925455 Free PMC article.
-
Alzheimer's Disease: An Updated Overview of Its Genetics.Int J Mol Sci. 2023 Feb 13;24(4):3754. doi: 10.3390/ijms24043754. Int J Mol Sci. 2023. PMID: 36835161 Free PMC article. Review.
-
DNA Methylation: A Promising Approach in Management of Alzheimer's Disease and Other Neurodegenerative Disorders.Biology (Basel). 2022 Jan 7;11(1):90. doi: 10.3390/biology11010090. Biology (Basel). 2022. PMID: 35053088 Free PMC article. Review.
-
Urinary Proteomics Identifying Novel Biomarkers for the Diagnosis and Phenotyping of Carotid Artery Stenosis.Front Mol Biosci. 2021 Aug 10;8:714706. doi: 10.3389/fmolb.2021.714706. eCollection 2021. Front Mol Biosci. 2021. PMID: 34447787 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical